DK2804587T3 - Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed - Google Patents
Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed Download PDFInfo
- Publication number
- DK2804587T3 DK2804587T3 DK13703152.2T DK13703152T DK2804587T3 DK 2804587 T3 DK2804587 T3 DK 2804587T3 DK 13703152 T DK13703152 T DK 13703152T DK 2804587 T3 DK2804587 T3 DK 2804587T3
- Authority
- DK
- Denmark
- Prior art keywords
- biodeless
- pharmaceuticals
- formulation
- procedure
- increasing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261588341P | 2012-01-19 | 2012-01-19 | |
US201261615457P | 2012-03-26 | 2012-03-26 | |
US201261696540P | 2012-09-04 | 2012-09-04 | |
US201261704893P | 2012-09-24 | 2012-09-24 | |
PCT/IL2013/050047 WO2013108254A1 (en) | 2012-01-19 | 2013-01-17 | Formulation and method for increasing oral bioavailability of drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2804587T3 true DK2804587T3 (da) | 2019-08-12 |
Family
ID=47678957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13703152.2T DK2804587T3 (da) | 2012-01-19 | 2013-01-17 | Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed |
Country Status (5)
Country | Link |
---|---|
US (2) | US20140348926A1 (da) |
EP (1) | EP2804587B1 (da) |
DK (1) | DK2804587T3 (da) |
ES (1) | ES2739194T3 (da) |
WO (1) | WO2013108254A1 (da) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2014013826A (es) | 2012-05-16 | 2018-04-24 | Singh Mewa | Composiciones farmaceuticas para la entrega de farmacos sustancialmente solubles en agua. |
WO2015057751A1 (en) | 2013-10-14 | 2015-04-23 | Nanosphere Health Sciences, Llc | Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers |
WO2015118549A1 (en) * | 2014-02-10 | 2015-08-13 | F&C Licorice Ltd. | Encapsulated biologically active agents |
US10213391B2 (en) | 2014-05-06 | 2019-02-26 | Mewa Singh | Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation |
US10117891B2 (en) | 2014-09-16 | 2018-11-06 | India Globalization Capital, Inc. | Cannabinoid composition for treating pain |
BR112017012434A2 (pt) * | 2014-12-12 | 2018-02-20 | Ojai Energetics Pbc | composições de canabinóide microencapsuladas |
US10350165B2 (en) | 2014-12-12 | 2019-07-16 | Ojai Energetics Pbc | Methods and systems for forming stable droplets |
CA3050535C (en) | 2014-12-15 | 2021-11-09 | Richard Clark Kaufman | Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of anti-inflammatory nutraceuticals |
US10751300B2 (en) | 2015-01-25 | 2020-08-25 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
WO2016144376A1 (en) | 2015-03-10 | 2016-09-15 | Nanosphere Health Sciences, Llc | Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms |
WO2017027651A1 (en) | 2015-08-12 | 2017-02-16 | India Globalization Capital, Inc. | Method and composition for treating cachexia and eating disorders |
CN115778928A (zh) * | 2015-08-28 | 2023-03-14 | 康霈生技股份有限公司 | 用于减少局部脂肪的医药组成物及其用途 |
EP3368014B1 (en) * | 2015-10-26 | 2023-10-04 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | Novel cannabinoid formulations |
WO2017074266A1 (en) * | 2015-10-30 | 2017-05-04 | National University Of Singapore | Androgen biosynthesis inhibitor |
EP3251668A1 (en) | 2016-06-02 | 2017-12-06 | Pharmotech SA | Cannabidiol compositions and uses thereof |
CA3027862A1 (en) | 2016-06-15 | 2017-12-21 | India Globalization Capital, Inc. | Method and composition for treating seizure disorders |
EP3290026A1 (en) | 2016-09-06 | 2018-03-07 | Athenion AG | Method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents |
IL248150B (en) | 2016-09-29 | 2018-05-31 | Garti Nissim | A method for selective extraction of cannabinoid from plant origin |
IL248149B (en) | 2016-09-29 | 2020-03-31 | Garti Nissim | Formulations of dilutable cannabinoids and processes for their preparation |
US10835501B2 (en) * | 2016-10-01 | 2020-11-17 | Indication Bioscience Llc | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
CN110087688B (zh) * | 2016-10-14 | 2023-05-05 | 希普拉有限公司 | 包含利福昔明的药物组合物 |
US20180169061A1 (en) * | 2016-12-15 | 2018-06-21 | Ascent Pharmaceuticals, Inc. | Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations |
EP3582755A4 (en) * | 2017-02-15 | 2020-12-23 | Molecular Infusions, LLC | FORMULATIONS |
US11261215B2 (en) | 2017-09-19 | 2022-03-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Somatostatin prodrugs |
EP3511325A1 (en) | 2018-01-11 | 2019-07-17 | MetrioPharm AG | Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione |
EP3536332A1 (en) | 2018-03-07 | 2019-09-11 | Athenion AG | Krill oil for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents |
IL261132A (en) | 2018-08-13 | 2018-11-04 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Preparations based on cannabis oil powders produced by the nanoemulsion method, methods for their preparation and use |
JP7326445B2 (ja) | 2018-12-11 | 2023-08-15 | ディスラプション・ラブズ・インコーポレイテッド | 治療剤の送達のための組成物並びにその使用及び製造方法 |
CN111632052A (zh) * | 2019-03-01 | 2020-09-08 | 沈阳药科大学 | 胡椒碱在制备sEH抑制剂中的应用 |
US20200375911A1 (en) * | 2019-06-03 | 2020-12-03 | Fresh Cut Development, Llc | Cannabidiol nanocrystal compositions |
AU2020342526A1 (en) * | 2019-09-06 | 2022-03-24 | Quicksilver Scientific, Inc. | Microemulsion delivery systems for water-based beverages |
US20210169820A1 (en) | 2019-09-12 | 2021-06-10 | Nulixir Inc. | Controlled release concentrate and suspensions including the same |
US11872197B2 (en) | 2020-03-03 | 2024-01-16 | Another Chance Nutra, LLC | Method of treatment or alleviating symptoms of a disorder with curcumin |
EP4114362A4 (en) * | 2020-03-05 | 2024-03-20 | Univ Miami | NANODRUG FORMULATIONS OF CANNABIDIOL AND THEIR METHODS OF USE |
EP3919046A1 (en) | 2020-06-02 | 2021-12-08 | Athenion AG | Method for solubilizing natural, endogenous and synthetic cannabinoids |
US20230277449A1 (en) * | 2020-07-15 | 2023-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Oral cavity polymeric delivery systems |
IL293086A (en) | 2020-07-29 | 2022-07-01 | Karnak Tech Llc | Formulations of orally administered lipophilic dietary supplements and beneficial oils |
KR20230047095A (ko) | 2020-07-29 | 2023-04-06 | 카낙 테크놀로지스, 엘엘씨 | 치료용 친유성 활성물질의 개선된 전달을 위한 약제학적 조성물 |
JP2024510051A (ja) | 2021-04-01 | 2024-03-05 | エスエヌジェー ファーマ インコーポレーテッド | 生理活性物質の経口用ナノ粒子及びその製造方法 |
US20220347119A1 (en) * | 2021-04-30 | 2022-11-03 | Reshma N. Kheraj | Medicated drink |
WO2023043855A1 (en) * | 2021-09-14 | 2023-03-23 | Nulixir Inc. | Oral compositions with plant matter extracts and methods of making the same |
EP4186497A1 (en) | 2021-11-26 | 2023-05-31 | Dorian Bevec | Alpha lipoic acid, epigallocatechin 3-gallate, and curcumin as a medicament for the treatment of arthritis or sars-cov-2 infection |
LU501323B1 (en) | 2022-01-25 | 2023-07-25 | Kemijski Inst | Cannabinoid complexes with improved properties |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN176897B (da) | 1993-10-29 | 1996-09-28 | Cadila Lab Ltd | |
US5439891A (en) | 1993-10-29 | 1995-08-08 | Kapil; Randhir S. | Process for preparation of pharmaceutical composition with enhanced activity for treatment of tuberculosis and leprosy |
US5536506A (en) | 1995-02-24 | 1996-07-16 | Sabinsa Corporation | Use of piperine to increase the bioavailability of nutritional compounds |
US5744161A (en) | 1995-02-24 | 1998-04-28 | Sabinsa Corporation | Use of piperine as a bioavailability enhancer |
US7919113B2 (en) | 1999-12-30 | 2011-04-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Dispersible concentrate lipospheres for delivery of active agents |
US20060148727A1 (en) * | 2004-12-01 | 2006-07-06 | Curt Hendrix | Folate based composition for neurological and cognitive applications |
PL1993365T3 (pl) * | 2006-03-06 | 2013-10-31 | Univ California | Preparaty z biodostępnych kurkuminoidów do leczenia choroby alzheimera oraz innych zaburzeń powiązanych z wiekiem |
US10960077B2 (en) * | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
WO2010010431A1 (en) * | 2008-07-24 | 2010-01-28 | National Institute Of Pharmaceutical Education And Research | Self-nano-emulsifying curcuminoids composition with enhanced bioavailability |
WO2010019255A1 (en) * | 2008-08-13 | 2010-02-18 | Virun, Inc. | Compositions containing aminoalkanes and aminoalkane derivatives |
ES2718090T3 (es) * | 2010-11-08 | 2019-06-27 | Cadila Pharmaceuticals Ltd | Composición farmacéutica de taxoides |
-
2013
- 2013-01-17 US US14/371,819 patent/US20140348926A1/en not_active Abandoned
- 2013-01-17 WO PCT/IL2013/050047 patent/WO2013108254A1/en active Application Filing
- 2013-01-17 EP EP13703152.2A patent/EP2804587B1/en active Active
- 2013-01-17 ES ES13703152T patent/ES2739194T3/es active Active
- 2013-01-17 DK DK13703152.2T patent/DK2804587T3/da active
-
2019
- 2019-09-20 US US16/577,609 patent/US20200009067A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2804587A1 (en) | 2014-11-26 |
EP2804587B1 (en) | 2019-05-08 |
ES2739194T3 (es) | 2020-01-29 |
WO2013108254A1 (en) | 2013-07-25 |
US20140348926A1 (en) | 2014-11-27 |
US20200009067A1 (en) | 2020-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2804587T3 (da) | Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed | |
DK3238709T3 (da) | Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme | |
DK2898061T3 (da) | Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande | |
DK2903600T3 (da) | Virusholdig formulering og anvendelse deraf | |
DK2917763T3 (da) | Lidar-målesystem og lidar-målefremgangsmåde | |
DK3608325T3 (da) | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse | |
DK2800565T3 (da) | Carbamatforbindelser og fremgangsmåder til fremstilling og anvendelse af samme | |
DK2929031T5 (da) | Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf | |
DK2854883T3 (da) | Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf | |
DK3252160T3 (da) | Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation | |
DK2920149T3 (da) | 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf | |
DK3550836T3 (da) | Fremgangsmåde og anordning til afkodning | |
DK2838533T3 (da) | Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet | |
DK2892912T3 (da) | C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf | |
DK2729151T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf | |
DK3050883T3 (da) | Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter | |
DK3007695T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
DK3080281T3 (da) | System til administration af mikrobiske inokulanter og relaterede materialer og fremgangsmåder | |
DK3049059T3 (da) | Intranasal dhe formulering til behandlingen af hovedpine | |
DK2867422T3 (da) | Anordning til armering af sammenføjninger og søjler i kombination | |
DK3025586T3 (da) | Sammensætning til bekæmpelse af plantesygdomme og anvendelse deraf | |
DK3010895T3 (da) | Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner | |
DK2922860T3 (da) | Hydrerede og vandfri polymorfer af 2'-o-fucosyllactose samt fremgangsmåder til fremstilling deraf | |
DK2908661T3 (da) | Mikroalgemelgranulater og fremgangsmåde til fremstilling deraf | |
DK2964767T3 (da) | Toksingener og fremgangsmåder til anvendelse deraf |